Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents-Reference-Cited by-同舟云学术

Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents

Published:2018-07-23 Issue:4 Volume:54 Page:497-507
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Chen Yi-Bin^ORCID,McCarthy Philip L.,Hahn Theresa,Holstein Sarah A.,Ueda Masumi^ORCID,Kröger Nicolaus,Bishop Michael,de Lima Marcos^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0269-3.pdf

Reference83 articles.

1. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109:2791–3. https://doi.org/10.1182/blood-2006-04-019836 . e-pub ahead of print 2006/11/23

2. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 2007;110:4614–7. https://doi.org/10.1182/blood-2007-04-082990 . e-pub ahead of print 2007/09/21

3. Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95:87–95. https://doi.org/10.3324/haematol.2009.011221 . e-pub ahead of print 2009/10/03

4. Caocci G, Vacca A, Ledda A, Murgia F, Piras E, Greco M, et al. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012;18:652–4. https://doi.org/10.1016/j.bbmt.2011.12.587 . e-pub ahead of print 2012/01/14

5. Teng CL, Yu JT, Chen HC, Hwang WL. Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. 2013;92:1137–9. https://doi.org/10.1007/s00277-012-1670-4 . e-pub ahead of print 2013/01/12

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Endoscopic Techniques in the Diagnosis of Complications of Allogeneic Hematopoietic Stem Cell Transplantation: A Review of the Literature;Journal of Clinical Medicine;2024-07-25

2. Outcomes of patients undergoing third hematopoietic cell transplantation for hematologic malignancies;Annals of Hematology;2024-07-14

3. MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation;BMC Cancer;2023-03-03

4. MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation;2022-09-30

5. Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation;Annals of Hematology;2022-03-29